Explore jobs
Find specific jobs
Explore careers
Explore professions
Best companies
Explore companies
Zippia finds jobs where you're a top candidate and applies on your behalf.
Cerevance received early financing of $21.5M on 2016-12-02.
| Series | Round size | Date |
|---|---|---|
| Series A | $21.5M | 12/2016 |
| Series A | $5M | 05/2017 |
| Series B | $65M | 04/2020 |
| Investors | Security type |
|---|---|
| Lightstone Ventures | Series A |
| Takeda Pharmaceutical | Series A |
| Lightstone Ventures | Series A |
| Takeda Pharmaceutical | Series A |
| SV Health Investors LLC | Series A |
| Dementia Discovery Fund (DDF) | Series A |
| UPMC Enterprises | Series B |
| Dolby Family Ventures | Series B |
| Lightstone Ventures | Series B |
| Takeda Ventures Inc | Series B |
| Foresite Capital | Series B |
| Bill Gates | Series B |
| GV | Series B |
| Dementia Discovery Fund (DDF) | Series B |
| Casdin Capital | Series B |
Cerevance's top competitor, Inozyme Pharma, earned an annual revenue of $2.2B.
Cerevance's smallest competitor is Sapience Therapeutics with revenue of $510.0K last year.
| Company name | Average salary | Revenue | Employee size | Job openings |
|---|---|---|---|---|
| Sapience Therapeutics | - | $510,000 | 15 | - |
| Expansion Therapeutics | - | $590,000 | 35 | - |
| Arrakis Therapeutics | - | $1.0M | 78 | - |
| Prelude Therapeutics | - | $7.0M | 70 | - |
| Inozyme Pharma | - | $2.2B | 20 | - |
| Tarsa Therapeutics | - | $1.6M | 10 | - |
| Turning Point Therapeutics | - | $25.0M | 142 | - |
Zippia gives an in-depth look into the details of Cerevance, including salaries, political affiliations, employee data, and more, in order to inform job seekers about Cerevance. The employee data is based on information from people who have self-reported their past or current employments at Cerevance. The data on this page is also based on data sources collected from public and open data sources on the Internet and other locations, as well as proprietary data we licensed from other companies. Sources of data may include, but are not limited to, the BLS, company filings, estimates based on those filings, H1B filings, and other public and private datasets. While we have made attempts to ensure that the information displayed are correct, Zippia is not responsible for any errors or omissions or for the results obtained from the use of this information. None of the information on this page has been provided or approved by Cerevance. The data presented on this page does not represent the view of Cerevance and its employees or that of Zippia.
Cerevance may also be known as or be related to Cerevance.